Phase I Clinical Study of Crenezumab in Patients with Alzheimer's Disease
Phase 1
Completed
- Conditions
- Alzheimer's disease(AD)
- Registration Number
- JPRN-jRCT2080223155
- Lead Sponsor
- CHUGAI PHARMACEUTICAL CO., LTD.
- Brief Summary
Crenezumab has an acceptable safety profile to Japanese patients with mild to moderate Alzheimer's Disease
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
Diagnosed as having probable AD dementia based on the NIA-AA core diagnostic criteria, or diagnosed as having mild to moderate dementia due to AD based on DSM-V
-MMSE score is 18 to 28 at screening
etc.
Exclusion Criteria
-Concurrent neurological disease other than AD that could affect cognitive function or history thereof.
-Meet the exclusion criteria of MRI at screening.
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method